Risk factors for coronary artery disease
Yıl: 2014 Cilt: 5 Sayı: 2 Sayfa Aralığı: 159 - 163 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Risk factors for coronary artery disease
Öz: Aterosklerotik koroner arter hastalığı tüm dünyada morbidite ve mortaliteninen önemli nedenidir. Koroner arter hastalığı risk faktörleri ilk olarak 1960ların erken dönemlerinde Framingham Kalp Çalışmasının bulguları ile belirlenmiştir. Bu faktörlerin anlaşılması, bir klinisyen için kardiyovasküler morbiditelerin ve mortalitenin önlenmesinde önemlidir. Bu derlemede, koroner arterhastalığı risk faktörlerini özetledik.
Anahtar Kelime: Konular:
Koroner arter hastalığı risk faktörleri
Öz: Atherosclerotic coronary artery disease is a major cause of morbidity and mortality in all over the world. Risk factors of coronary artery disease were first determined with findings of the Framingham Heart Study in the early 1960s. The understanding of these factors is critical for a clinician to prevent cardiovascular morbidities and mortality. In this review, we summarised the risk factors of the coronary artery disease.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372(9638):570- 84.
- 2. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104(3):365-72.
- 3. Onat A, Kahraman G, Ökçün B, Dönmez K, Keleş İ, Sansoy V. Türk Erişkinlerinde Ölüm ve Koroner Olaylar: TEKHARF Çalışması Kohortunun 5-Yıllık Takibi. Türk Kardiyol Dern Arş 1996;24(1):8-15.
- 4. Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002;13(Suppl.1):1-6.
- 5. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994;89(5):2462-78.
- 6. Stary HC. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol 2000;20(5):1177-8.
- 7. Moreno PR, Purushothaman KR, Fuster V, OConnor WN. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. Circulation 2002;105(21):2504-11.
- 8. Zoghi M, Nalbantgil I. Hypertension and endothelial dysfunction. Anadolu Kardiyol Derg 2002;2(2):142-7.
- 9. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001;12(4):383-9.
- 10. Zengin E, Chalajour F, Gehling UM, Ito WD, Treede H, Lauke H et al. Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development 2006;133(8):1543-51.
- 11. Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004;15(8):1983-92.
- 12. Landmesser U, Drexler H. The clinical significance of endothelial dysfunction. Curr Opin Cardiol 2005;20(6):547-51.
- 13. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc 2009;84(10):917-38.
- 14. Hamm CW, Möllmann, H, Bassand JP, Van de Werf F. Acute Coronary Syndrom. In: Camm AJ, Lücher TF, Serruys PW,editors. The ESC Textbook of Cardiovascular Medicine. 2nd ed.New York: Oxford Universty Press; 2009. P535-97.
- 15. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003;138(11):891-7.
- 16. Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999;25(3):199-211.
- 17. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78.
- 18. Brewer HB, Jr. Increasing HDL Cholesterol Levels. N Engl J Med 2004;350(15):1491-4.
- 19. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14 (Suppl. 2):1-40.
- 20. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5):383-93.
- 21. Scheuner MT. Genetic evaluation for coronary artery disease. Genet Med 2003;5(4):269-85.
- 22. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation 2004;110(13):1868-73.
- 23. Lusis AJ, Fogelman AM, Fonarow GC. Genetic basis of atherosclerosis: part II: clinical implications. Circulation 2004;110(14):2066-71.
- 24. Graham IM. The importance of total cardiovascular risk assessment in clinical practice. Eur J Gen Pract 2006;12(4):148-55.
- 25. Güleç S. Kalp damar hastalıklarında global risk ve hedefler. Türk Kardiyol Dern Arş 2009;37(Suppl. 2):1-10.
- 26. Tavlı T, Pekel N. Koroner Arter Hastalığında Risk Faktörleri. Turkiye Klinikleri J Cardiol-Special Topics 2011;4(2):16-20.
- 27. Cortese C, Motti C. MTHFR gene polymorphism, homocysteine and cardiovascular disease. Public Health Nutr 2001;4(2):493-7.
- 28. Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardio- cerebrovascular risk. J Appl Genet 2008;49(3):267-82.
- 29. McDowell IF, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr 2000;130(Suppl.2):369-72.
- 30. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325(7374):1202.
- 31. Yıldırır A. Yeni bir risk faktörü olarak yüksek duyarlıklı C-reaktif protein (hsCRP). Türk Kardiyol Dern Arş 2005;33(6):360-71.
- 32. Smith EB, Thompson WD, Crosbie L, Stirk CM. Fibrinogen/fibrin in atherogenesis. Eur J Epidemiol 1992;8(Suppl. 1):83-7.
- 33. Koylan N. Lipoprotein (a) ve ateroskleroz. Türk Kardiyol Dern Arş 1999;27(7):483-90.
| APA | Bugan B, ÇELİK T (2014). Risk factors for coronary artery disease. , 159 - 163. |
| Chicago | Bugan Baris,ÇELİK Turgay Risk factors for coronary artery disease. (2014): 159 - 163. |
| MLA | Bugan Baris,ÇELİK Turgay Risk factors for coronary artery disease. , 2014, ss.159 - 163. |
| AMA | Bugan B,ÇELİK T Risk factors for coronary artery disease. . 2014; 159 - 163. |
| Vancouver | Bugan B,ÇELİK T Risk factors for coronary artery disease. . 2014; 159 - 163. |
| IEEE | Bugan B,ÇELİK T "Risk factors for coronary artery disease." , ss.159 - 163, 2014. |
| ISNAD | Bugan, Baris - ÇELİK, Turgay. "Risk factors for coronary artery disease". (2014), 159-163. |
| APA | Bugan B, ÇELİK T (2014). Risk factors for coronary artery disease. Journal of Clinical and Analytical Medicine, 5(2), 159 - 163. |
| Chicago | Bugan Baris,ÇELİK Turgay Risk factors for coronary artery disease. Journal of Clinical and Analytical Medicine 5, no.2 (2014): 159 - 163. |
| MLA | Bugan Baris,ÇELİK Turgay Risk factors for coronary artery disease. Journal of Clinical and Analytical Medicine, vol.5, no.2, 2014, ss.159 - 163. |
| AMA | Bugan B,ÇELİK T Risk factors for coronary artery disease. Journal of Clinical and Analytical Medicine. 2014; 5(2): 159 - 163. |
| Vancouver | Bugan B,ÇELİK T Risk factors for coronary artery disease. Journal of Clinical and Analytical Medicine. 2014; 5(2): 159 - 163. |
| IEEE | Bugan B,ÇELİK T "Risk factors for coronary artery disease." Journal of Clinical and Analytical Medicine, 5, ss.159 - 163, 2014. |
| ISNAD | Bugan, Baris - ÇELİK, Turgay. "Risk factors for coronary artery disease". Journal of Clinical and Analytical Medicine 5/2 (2014), 159-163. |
